The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).
 
Michael Ong
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Novartis / AAA; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Pfizer/EMD Serono; Sanofi
Research Funding - AstraZeneca (Inst); BMS (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen
 
Kim Chi
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Janssen; Merck; Novartis; Pfizer; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; Janssen; Merck; POINT Biopharma; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Sebastien Hotte
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Scientific and Medical Affairs Inc; Bayer
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst); SignalChem (Inst)
 
Eric Winquist
Consulting or Advisory Role - Bayer; Eisai; EMD Serono; Ipsen; Merck; Roche
Research Funding - Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Research Funding - Abbvie (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Point Therapeutics (Inst); Sanofi (Inst)
 
Cristiano Ferrario
Honoraria - AstraZeneca; Bayer; Janssen Oncology; Merck; Novartis; Pfizer; Roche Canada; Seagen
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Merck; Novartis; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Robyn Macfarlane
Honoraria - IPSEN
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genzyme; Janssen; Merck; Novartis Canada Pharmaceuticals Inc
 
Michael Kolinsky
Honoraria - AstraZeneca; Bayer; Eisai; EMD Serono; Janssen; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck
Research Funding - Janssen (Inst)
 
Aaron Hansen
Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; Janssen; Merck
Research Funding - Advancell (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Muhammad Salim
No Relationships to Disclose
 
Christian Kollmannsberger
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Merck KGaA; Pfizer; Seagen
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen; Merck; Merck KGaA; Pfizer; Seagen
Travel, Accommodations, Expenses - AAA Canada; Ipsen; Janssen Oncology; Pfizer
 
Aly-Khan Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - BioCanRx (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Roche (Inst)
 
Lesley Seymour
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Repare Therapeutics (Inst)
 
Som Mukherjee
Speakers' Bureau - EMD Serono
Travel, Accommodations, Expenses - Amgen
 
Edmond Kwan
No Relationships to Disclose
 
Max Sherry
No Relationships to Disclose
 
Dongsheng Tu
No Relationships to Disclose
 
Mariam Jafri
No Relationships to Disclose
 
Alexander Wyatt
Honoraria - AstraZeneca; Bayer; Janssen; Merck; Pfizer
Research Funding - ESSA (Inst); Promontory Therapeutics (Inst); Tyra Biosciences (Inst)
 
Wei Tu
No Relationships to Disclose